BriaCell Therapeutics Corp.BCTXNASDAQ
Loading
EPS Growth Under PressureDecelerating
Percentile Rank56
5Y CAGR-5.9%
Year-over-Year Change
Year-over-year earnings per share growth rate
5Y CAGR
-5.9%/yr
Long-term compound
Percentile
P56
Within normal range
vs 5Y Ago
0.7x
Contraction
Streak
1 qtr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| Q4 2025 | 25.89% |
| Q3 2025 | 74.84% |
| Q2 2025 | 30.50% |
| Q1 2025 | 24.65% |
| Q4 2024 | -220.27% |
| Q3 2024 | -164.16% |
| Q2 2024 | 115.13% |
| Q1 2024 | -289.18% |
| Q4 2023 | 349.87% |
| Q3 2023 | 52.95% |
| Q2 2023 | 58.55% |
| Q1 2023 | -995.63% |
| Q4 2022 | -3151.83% |
| Q3 2022 | 99.65% |
| Q2 2022 | -192.08% |
| Q1 2022 | 139.49% |
| Q4 2021 | -1582.87% |
| Q3 2021 | -117.20% |
| Q2 2021 | 308.30% |
| Q1 2021 | 39.95% |
| Q4 2020 | 35.02% |
| Q3 2020 | 1.48% |
| Q2 2020 | 62.49% |
| Q1 2020 | -16054.13% |
| Q4 2019 | 99.38% |
| Q3 2019 | 99.67% |
| Q2 2019 | -26580.59% |
| Q1 2019 | -49.12% |
| Q4 2018 | 51.64% |
| Q3 2018 | -34.49% |
| Q2 2018 | 0.49% |
| Q1 2018 | -1.38% |
| Q4 2017 | 0.57% |
| Q3 2017 | 12.40% |
| Q2 2017 | -175.42% |
| Q1 2017 | -771.06% |
| Q4 2016 | -1667.77% |
| Q3 2016 | 19.87% |
| Q2 2016 | 49.50% |
| Q1 2016 | 81.60% |